0.05 0.07 31826221 30526571 0001434524--12-31 2022 Q1 false P3Y P0Y P0Y 0 0 32154746 31581666 P2Y P1Y P12M P3Y 0001434524 us-gaap:RetainedEarningsMember 2022-03-31 0001434524 us-gaap:ParentMember 2022-03-31 0001434524 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001434524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001434524 us-gaap:RetainedEarningsMember 2021-12-31 0001434524 us-gaap:ParentMember 2021-12-31 0001434524 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001434524 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001434524 us-gaap:RetainedEarningsMember 2021-03-31 0001434524 us-gaap:ParentMember 2021-03-31 0001434524 us-gaap:NoncontrollingInterestMember 2021-03-31 0001434524 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001434524 us-gaap:RetainedEarningsMember 2020-12-31 0001434524 us-gaap:ParentMember 2020-12-31 0001434524 us-gaap:NoncontrollingInterestMember 2020-12-31 0001434524 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001434524 us-gaap:CommonStockMember 2022-03-31 0001434524 us-gaap:CommonStockMember 2021-12-31 0001434524 us-gaap:CommonStockMember 2021-03-31 0001434524 us-gaap:CommonStockMember 2020-12-31 0001434524 us-gaap:CommonStockMember clir:AtMarketOfferingMember 2022-03-31 0001434524 clir:AtMarketOfferingMember 2022-03-31 0001434524 srt:ChiefExecutiveOfficerMember us-gaap:EmployeeStockOptionMember clir:NonQualifiedStockOptionMember 2019-01-01 2019-12-31 0001434524 clir:ConsultantPlanMember 2022-03-31 0001434524 clir:ConsultantPlanMember 2021-12-31 0001434524 clir:EquityIncentivePlanMember 2022-01-01 2022-03-31 0001434524 clir:EquityIncentivePlanMember 2021-01-01 2021-12-31 0001434524 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001434524 us-gaap:StockOptionMember 2022-01-01 2022-03-31 0001434524 clir:EquityIncentivePlanMember 2022-01-01 2022-03-31 0001434524 srt:MinimumMember clir:PropertyPlantAndEquipmentOtherThanLeaseholdImprovementsMember 2022-01-01 2022-03-31 0001434524 srt:MaximumMember clir:PropertyPlantAndEquipmentOtherThanLeaseholdImprovementsMember 2022-01-01 2022-03-31 0001434524 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001434524 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001434524 clir:MinorityShareholderMember 2022-03-31 0001434524 us-gaap:MachineryAndEquipmentMember 2022-03-31 0001434524 us-gaap:MachineryAndEquipmentMember 2021-12-31 0001434524 srt:MinimumMember clir:SeattleAndTulsaMember 2022-03-31 0001434524 srt:MaximumMember clir:SeattleAndTulsaMember 2022-03-31 0001434524 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2022-03-31 0001434524 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2021-12-31 0001434524 us-gaap:FurnitureAndFixturesMember 2022-03-31 0001434524 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001434524 clir:TrademarksPendingMember 2022-03-31 0001434524 clir:RegisteredTrademarksMember 2022-03-31 0001434524 clir:TrademarksPendingMember 2021-12-31 0001434524 clir:RegisteredTrademarksMember 2021-12-31 0001434524 clir:PatentsPendingMember 2022-03-31 0001434524 clir:IssuedPatentsMember 2022-03-31 0001434524 clir:PatentsPendingMember 2021-12-31 0001434524 clir:IssuedPatentsMember 2021-12-31 0001434524 us-gaap:TrademarksMember 2022-01-01 2022-03-31 0001434524 srt:MinimumMember 2022-01-01 2022-03-31 0001434524 srt:MaximumMember 2022-01-01 2022-03-31 0001434524 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-03-31 0001434524 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-03-31 0001434524 clir:AtMarketFacilityMember 2022-03-31 0001434524 clir:PaycheckProtectionProgramLoanMember 2020-05-08 2020-05-08 0001434524 clir:PaycheckProtectionProgramLoanMember 2020-05-08 0001434524 clir:LossContractMember 2022-01-01 2022-03-31 0001434524 clir:BurnerContractMember 2022-01-01 2022-03-31 0001434524 clir:BurnerContractMember 2021-01-01 2021-03-31 0001434524 clir:EquityIncentivePlanMember 2022-03-31 0001434524 clir:EquityIncentivePlanMember 2021-12-31 0001434524 2021-03-31 0001434524 2020-12-31 0001434524 country:CN 2021-12-31 0001434524 2021-01-01 2021-12-31 0001434524 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-01-01 2022-03-31 0001434524 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001434524 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001434524 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2021-12-31 0001434524 2022-05-04 0001434524 clir:ConsultantPlanMember 2021-01-01 2021-03-31 0001434524 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-01-01 2022-03-31 0001434524 clir:ParticipationRightMember 2018-07-31 2018-07-31 0001434524 clir:ParticipationRightMember 2018-07-31 0001434524 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001434524 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001434524 us-gaap:ParentMember 2022-01-01 2022-03-31 0001434524 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001434524 clir:TwoThousandAndTwentyOnePlanMember 2021-06-17 2021-06-17 0001434524 clir:SeattleAndTulsaMember 2021-01-01 2021-03-31 0001434524 2020-01-01 2020-12-31 0001434524 2021-12-31 0001434524 srt:MinimumMember clir:SeattleAndTulsaMember 2022-01-01 2022-03-31 0001434524 srt:MaximumMember clir:SeattleAndTulsaMember 2022-01-01 2022-03-31 0001434524 country:CN 2022-01-01 2022-03-31 0001434524 clir:SeattleAndTulsaMember 2022-01-01 2022-03-31 0001434524 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-03-31 0001434524 clir:AtMarketFacilityMember 2022-01-01 2022-03-31 0001434524 clir:ConsultantPlanMember 2022-01-01 2022-03-31 0001434524 us-gaap:CommonStockMember clir:AtMarketOfferingMember 2022-01-01 2022-03-31 0001434524 clir:PaycheckProtectionProgramLoanMember 2021-04-01 2021-06-30 0001434524 2022-03-31 0001434524 2022-01-01 2022-03-31 0001434524 country:CN 2022-03-31 0001434524 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-01-01 2022-03-31 0001434524 clir:AtMarketOfferingMember 2022-01-01 2022-03-31 0001434524 us-gaap:ParentMember 2021-01-01 2021-03-31 0001434524 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001434524 2021-01-01 2021-03-31 iso4217:USD iso4217:USD xbrli:shares clir:project xbrli:pure clir:employee xbrli:shares

Table of Contents

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the quarterly period ended March 31, 2022

OR

​

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the transition period from ______________ to _______________

Commission File Number 001-35521

CLEARSIGN TECHNOLOGIES CORPORATION

(Exact name of registrant as specified in its charter)

​

Washington (State or other jurisdiction of incorporation or organization) |  | 26-2056298 (I.R.S. Employer Identification No.)

​

8023 E. 63rd Place, Suite 101

Tulsa, Oklahoma 74133

(Address of principal executive offices)

(Zip Code)

​

(206) 673-4848

(Registrant’s telephone number, including area code)

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock | ​ | CLIR | ​ | The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period than the registrant was required to submit such files). Yes ⌧ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

Large accelerated filer ☐ |  | Accelerated filer ☐
Non-accelerated filer ⌧ |  | Smaller reporting company ☒
​ | ​ | ​
|  | Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ⌧

​

As of May 4, 2022, the issuer has 32,160,131 shares of common stock, par value $0.0001, issued and outstanding.

​

​

​

Table of Contents

​

TABLE OF CONTENTS

​

​ | ​ | ​
PART I | FINANCIAL INFORMATION | ​
​ | ​ | ​
Item 1. | Unaudited Condensed Consolidated Financial Statements | ​
​ | ​ | ​
​ | Unaudited Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 | 1
​ | ​ | ​
​ | Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and, 2021 | 2
​ | ​ | ​
​ | Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the three month periods ended March 31, 2022 and 2021 | 3
​ | ​ | ​
​ | Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021 | 4
​ | ​ | ​
​ | Notes to Unaudited Condensed Consolidated Financial Statements | 5
​ | ​ | ​
Item 2. | Management’s Discussion and Analysis of Financial Conditions and Results of Operations | 18
​ | ​ | ​
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 23
​ | ​ | ​
Item 4. | Controls and Procedures | 23
​ | ​ | ​
PART II | OTHER INFORMATION | 24
​ | ​ | ​
Item 1. | Legal Proceedings | 24
​ | ​ | ​
Item 1A. | Risk Factors | 24
​ | ​ | ​
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 24
​ | ​ | ​
Item 3. | Defaults Upon Senior Securities | 24
​ | ​ | ​
Item 4. | Mine Safety Disclosures | 24
​ | ​ | ​
Item 5. | Other Information | 24
​ | ​ | ​
Item 6. | Exhibits | 25
​ | ​ | ​
​ | SIGNATURES | 26

​

​

​

​

​

​

​

​

Table of Contents

​

PART I-FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ClearSign Technologies Corporation and Subsidiary

Condensed Consolidated Balance Sheets

(Unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(in thousands, except share and per share data) | ​ | March 31, | ​ | December 31, | ​
​ |  | 2022 |  | 2021 |
ASSETS | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Current Assets: |  | ​ |  |  | ​ |  |
Cash and cash equivalents | ​ | $ | 6,667 | ​ | $ | 7,607 | ​
Accounts receivable, net | ​ | ​ | 27 | ​ | ​ | 33 | ​
Contract assets | ​ |  | 244 | ​ |  | 39 | ​
Prepaid expenses and other assets | ​ |  | 401 | ​ |  | 345 | ​
Total current assets | ​ |  | 7,339 | ​ |  | 8,024 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Fixed assets, net | ​ |  | 493 | ​ |  | 530 | ​
Patents and other intangible assets, net | ​ |  | 802 | ​ |  | 799 | ​
Other assets | ​ |  | 10 | ​ |  | 10 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total Assets | ​ | $ | 8,644 | ​ | $ | 9,363 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
LIABILITIES AND EQUITY | ​ |  |  | ​ |  |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Current Liabilities: | ​ |  | ​ | ​ |  |  | ​
Accounts payable and accrued liabilities | ​ | $ | 294 | ​ | $ | 224 | ​
Current portion of lease liabilities | ​ |  | 212 | ​ |  | 205 | ​
Accrued compensation and related taxes | ​ |  | 196 | ​ |  | 218 | ​
Contract liabilities | ​ | ​ | 84 | ​ | ​ | 84 | ​
Total current liabilities | ​ |  | 786 | ​ |  | 731 | ​
Long Term Liabilities: | ​ |  | ​ | ​ |  | ​ | ​
Long term lease liabilities | ​ |  | 294 | ​ | ​ | 350 | ​
Total liabilities | ​ |  | 1,080 | ​ |  | 1,081 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Commitments and contingencies (note 7) | ​ |  | ​ | ​ |  | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Stockholders’ Equity: | ​ |  |  | ​ |  |  | ​
Preferred stock, $0.0001 par value, zero shares issued and outstanding | ​ |  | — | ​ |  | — | ​
Common stock, $0.0001 par value, 32,154,746 and 31,581,666 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively | ​ |  | 3 | ​ | ​ | 3 | ​
Additional paid-in capital | ​ |  | 91,807 | ​ | ​ | 91,035 | ​
Accumulated other comprehensive income | ​ | ​ | 9 | ​ | ​ | 9 | ​
Accumulated deficit | ​ |  | (84,255) | ​ | ​ | (82,765) | ​
Total ClearSign Technologies Corporation stockholders' equity | ​ | ​ | 7,564 | ​ | ​ | 8,282 | ​
Noncontrolling Interest | ​ | ​ | — | ​ | ​ | — | ​
Total equity | ​ |  | 7,564 | ​ |  | 8,282 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total Liabilities and Equity | ​ | $ | 8,644 | ​ | $ | 9,363 | ​

​

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

​

1

Table of Contents

​

ClearSign Technologies Corporation and Subsidiary

Condensed Consolidated Statements of Operations

(Unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(in thousands, except share and per share data) | ​ | For the Three Months Ended | ​
​ | ​ | March 31, | ​
​ |  | 2022 |  | 2021 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Revenues | ​ | $ | — | ​ | $ | 363 | ​
Cost of goods sold | ​ |  | — | ​ |  | 225 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gross Income | ​ |  | — | ​ |  | 138 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating expenses: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development | ​ |  | 108 | ​ |  | 826 | ​
General and administrative | ​ |  | 1,409 | ​ |  | 1,333 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total operating expenses | ​ |  | 1,517 | ​ |  | 2,159 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Loss from operations | ​ |  | (1,517) | ​ |  | (2,021) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other income | ​ | ​ | ​ | ​ | ​ | ​ | ​
Gain from sale of assets | ​ | ​ | 23 | ​ | ​ | — | ​
Other income, net | ​ | ​ | 4 | ​ | ​ | — | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net Loss | ​ | $ | (1,490) | ​ | $ | (2,021) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net loss per share - basic and fully diluted | ​ | $ | (0.05) | ​ | $ | (0.07) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted average number of shares outstanding - basic and fully diluted | ​ |  | 31,826,221 | ​ |  | 30,526,571 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

​

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

​

2

Table of Contents

ClearSign Technologies Corporation and Subsidiary

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

For the Three Months Ended March 31, 2022 and 2021

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Total ClearSign | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​ | ​ | Technologies Corp. | ​ | ​ | ​ | ​ | ​ | ​
(in thousands, except per share data) | ​ | Common Stock | ​ | Additional | ​ | Comprehensive | ​ | Accumulated | ​ | Stockholders’ | ​ | Noncontrolling | ​ | ​
​ |  | Shares |  | Amount |  | Paid-In Capital |  | ​ | Income |  | Deficit |  | Equity |  | Interest |  | Total Equity
Balances at December 31, 2021 |  | 31,582 | ​ | $ | 3 | ​ | $ | 91,035 | ​ | $ | 9 | ​ | $ | (82,765) | ​ | $ | 8,282 | ​ | $ | — | ​ | $ | 8,282
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Shares issued upon exercise of options ($0.89 per share) | ​ | 1 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Shares issued upon exercise of options ($2.93 per share) | ​ | 3 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | —
Fair value of stock issued in payment of accrued compensation | ​ | 66 | ​ | ​ | — | ​ | ​ | 95 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 95 | ​ | ​ | — | ​ | ​ | 95
Fair value of stock options granted in payment of accrued compensation | ​ | — | ​ | ​ | — | ​ | ​ | 12 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 12 | ​ | ​ | — | ​ | ​ | 12
Share based compensation | ​ | 3 | ​ | ​ | — | ​ | ​ | 80 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 80 | ​ | ​ | — | ​ | ​ | 80
Shares issued through the use of At-The Market issuance ($1.24 average per share) | ​ | 496 | ​ | ​ | — | ​ | ​ | 578 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 578 | ​ | ​ | — | ​ | ​ | 578
Shares issued for services ($1.93 per share) | ​ | 4 | ​ | ​ | — | ​ | ​ | 7 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 7 | ​ | ​ | — | ​ | ​ | 7
Foreign-Exchange Translation Adjustment | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | —
Net loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (1,490) | ​ | ​ | (1,490) | ​ | ​ | — | ​ | ​ | (1,490)
Balances at March 31, 2022 |  | 32,155 | ​ | $ | 3 | ​ | $ | 91,807 | ​ | $ | 9 | ​ | $ | (84,255) | ​ | $ | 7,564 | ​ | $ | — | ​ | $ | 7,564

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Total ClearSign | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​ | ​ | Technologies Corp. | ​ | ​ | ​ | ​ | ​
​ | ​ | Common Stock | ​ | Additional | ​ | Comprehensive | ​ | Accumulated | ​ | Stockholders’ | ​ | Noncontrolling | ​ | ​
​ |  | Shares |  | Amount |  | Paid-In Capital |  | ​ | Income |  | Deficit |  | Equity |  | Interest |  | Total Equity
Balances at December 31, 2020 |  | 30,077 | ​ | $ | 3 | ​ | $ | 84,411 | ​ | $ | — | ​ | $ | (74,874) | ​ | $ | 9,540 | ​ | $ | 1 | ​ | $ | 9,541
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | ​
Shares issued upon exercise of options ($1.90 per share) | ​ | 1 | ​ | ​ | — | ​ | ​ | 2 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2 | ​ | ​ | — | ​ | ​ | 2
Shares issued upon exercise of options ($3.80 per share) | ​ | 9 | ​ | ​ | — | ​ | ​ | 36 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 36 | ​ | ​ | — | ​ | ​ | 36
Shares issued upon exercise of options ($1.21 per share) | ​ | 3 | ​ |  | — | ​ |  | 4 | ​ | ​ | — | ​ |  | — | ​ | ​ | 4 | ​ | ​ | — | ​ |  | 4
Shares issued upon exercise of warrants ($1.80 per share) | ​ | 38 | ​ |  | — | ​ |  | 67 | ​ | ​ | — | ​ |  | — | ​ | ​ | 67 | ​ | ​ | — | ​ |  | 67
Fair value of stock options issued for board service | ​ | — | ​ | ​ | — | ​ | ​ | 210 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 210 | ​ | ​ | — | ​ | ​ | 210
Fair value of stock issued in payment of accrued compensation | ​ | 64 | ​ | ​ | — | ​ | ​ | 217 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 217 | ​ | ​ | — | ​ | ​ | 217
Share based compensation | ​ | — | ​ | ​ | — | ​ | ​ | 410 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 410 | ​ | ​ | — | ​ | ​ | 410
Shares issued through use of At The Market issuance ($ 4.84 average per share) | ​ | 941 | ​ | ​ | — | ​ | ​ | 4,469 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 4,469 | ​ | ​ | — | ​ | ​ | 4,469
Proceeds receivable from At The Market issuance | ​ | — | ​ | ​ | — | ​ | ​ | (1,076) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (1,076) | ​ | ​ | — | ​ | ​ | (1,076)
Shares issued for services ($2.33 per share) | ​ | 4 | ​ | ​ | — | ​ | ​ | 9 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 9 | ​ | ​ | — | ​ | ​ | 9
Net loss | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (2,021) | ​ | ​ | (2,021) | ​ | ​ | — | ​ | ​ | (2,021)
Balances at March 31, 2021 | ​ | 31,137 | ​ | $ | 3 | ​ | $ | 88,759 | ​ | $ | — | ​ | $ | (76,895) | ​ | $ | 11,867 | ​ | $ | 1 | ​ | $ | 11,868

​

​

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

​

3

Table of Contents

ClearSign Technologies Corporation and Subsidiary

Condensed Consolidated Statements of Cash Flows

(Unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
(in thousands) | ​ | For the Three Months Ended March 31, | ​
​ |  | 2022 |  | 2021 |
Cash flows from operating activities: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net loss | ​ | $ | (1,490) | ​ | $ | (2,021) | ​
Adjustments to reconcile net loss to net cash used in operating activities: | ​ |  | ​ | ​ | ​ | ​ | ​
Common stock issued for services | ​ |  | 7 | ​ | ​ | 9 | ​
Share based compensation | ​ |  | 80 | ​ | ​ | 620 | ​
Depreciation and amortization | ​ |  | 36 | ​ | ​ | 46 | ​
Gain from sale of fixed assets | ​ | ​ | (23) | ​ | ​ | — | ​
Reserve for prepaid materials | ​ | ​ | — | ​ | ​ | 96 | ​
Change in operating assets and liabilities: | ​ |  | ​ | ​ | ​ | ​ | ​
Contract assets | ​ |  | (205) | ​ | ​ | (247) | ​
Accounts receivable | ​ |  | 6 | ​ | ​ | (124) | ​
Prepaid expenses and other assets | ​ |  | (56) | ​ | ​ | 127 | ​
Accounts payable and accrued liabilities | ​ |  | 57 | ​ | ​ | 2 | ​
Accrued compensation and related taxes | ​ |  | 85 | ​ | ​ | 25 | ​
Contract liabilities | ​ | ​ | — | ​ | ​ | (46) | ​
Net cash used in operating activities | ​ |  | (1,503) | ​ |  | (1,513) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash flows from investing activities: | ​ |  |  | ​ |  |  | ​
Acquisition of fixed assets | ​ |  | (5) | ​ | ​ | (54) | ​
Disbursements for patents and other intangible assets | ​ |  | (33) | ​ | ​ | (34) | ​
Proceeds from sale of fixed assets | ​ | ​ | 23 | ​ | ​ | — | ​
Net cash used in investing activities | ​ |  | (15) | ​ |  | (88) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash flows from financing activities: | ​ |  |  | ​ |  |  | ​
Proceeds from issuance of common stock, net of offering costs | ​ |  | 578 | ​ |  | 3,393 | ​
Proceeds from exercise of stock options and warrants | ​ | ​ | — | ​ | ​ | 109 | ​
Net cash provided by financing activities | ​ |  | 578 | ​ |  | 3,502 | ​
Cash and cash equivalents: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net change in cash and cash equivalents | ​ |  | (940) | ​ | ​ | 1,901 | ​
Cash and cash equivalents, beginning of period | ​ |  | 7,607 | ​ | ​ | 8,824 | ​
Cash and cash equivalents, end of period | ​ | $ | 6,667 | ​ | $ | 10,725 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Supplemental disclosure of cash flow information: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Officer and employee equity awards for prior year accrued compensation | ​ | $ | 107 | ​ | $ | 217 | ​

​

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

​

4

Table of Contents

ClearSign Technologies Corporation

Notes to Unaudited Condensed Consolidated Financial Statements

Note 1 – Organization and Description of Business

ClearSign Technologies Corporation (“ClearSign” or the “Company”) designs and develops products and technologies that have been shown to significantly improve key performance characteristics of industrial and commercial systems, including operational performance, energy efficiency, emission reduction, safety, and overall cost-effectiveness. The Company’s patented technologies are designed to be embedded in established OEM products as ClearSign Core™ and ClearSign Eye™ and other sensing configurations in order to enhance the performance of combustion systems and fuel safety systems in a broad range of markets. These markets include energy (upstream oil production and down-stream refining), commercial/industrial boiler, chemical, petrochemical, transport and power industries. The Company’s primary technology is its ClearSign Core technology, which achieves very low emissions without the need of external flue gas recirculation, selective catalytic reduction, or higher excess air operation.

The Company was incorporated in the State of Washington in 2008. During January 2022, the Company relocated its headquarters from Seattle, Washington to Tulsa, Oklahoma. On July 28, 2017, the Company incorporated a subsidiary, ClearSign Asia Limited, in Hong Kong to represent the Company’s business and technological interests throughout Asia. Through ClearSign Asia Limited, the Company has established a Wholly Foreign Owned Enterprise (WFOE) in China – ClearSign Combustion (Beijing) Environmental Technologies Co., LTD.

Unless otherwise stated or the context otherwise requires, the terms ClearSign and the Company refer to ClearSign Technologies Corporation and its subsidiary, ClearSign Asia Limited.

Liquidity

The Company's financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company’s technologies are currently in field development, but with nominal fully operational commercial installations, and have generated nominal revenues from operations to date to meet operating expenses. In order to generate meaningful revenues, the technologies must be fully developed, gain market recognition and acceptance, and develop a critical level of successful sales and product installations.

The Company has recently financed its operations primarily through issuances of equity securities including $6.1 million in gross proceeds raised from its At-The-Market (ATM) program in which the Company issued a total of 1.6 million shares of common stock at a weighted average price of $3.85 per share as of March 31, 2022. Costs associated with the ATM program totaled approximately $227 thousand and the Company received net cash proceeds approximating $5.9 million.

The Company has incurred losses since its inception totaling $84.3 million and expects to experience operating losses and negative cash flows for the foreseeable future. Management believes that the successful growth and operation of the Company’s business is dependent upon our ability to obtain adequate sources of funding through co-development agreements, strategic partnering agreements, or equity or debt financing to adequately support product commercialization efforts, protect intellectual property, form relationships with strategic partners, and provide for working capital and general corporate purposes. There can be no assurance that the Company will be successful in achieving its long-term plans as set forth above, or that such plans, if consummated, will result in profitable operations or enable the Company to continue in the long-term as a going concern.

​

5

Table of Contents

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for Form 10-Q. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, 2021 has been derived from the Company’s audited financial statements as of that date.

In the opinion of management, these condensed consolidated financial statements reflect all normal recurring and other adjustments necessary for a fair presentation. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Operating results for interim periods are not necessarily indicative of operating results for an entire fiscal year or any other future periods.

The accompanying unaudited condensed consolidated financial statements include the accounts of ClearSign and its subsidiary. Intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Revenue Recognition and Cost of Sales

The Company recognizes revenue and related cost of goods sold in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification 606 Revenue from Contracts with Customers (ASC 606). When applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the performance obligations are satisfied. Revenues and cost of goods sold are recognized once the goods or services are delivered to the customer’s control or non-refundable performance obligations are satisfied. The Company’s contracts with customers generally have performance obligations and a schedule of non-refundable cancellation obligations. The contracts generally will be fully performed upon delivery of certain drawings or equipment. Revenue related to the contracts is recognized following the completion of non-refundable performance obligations as defined in the contract.

The Company’s contracts generally include progress payments from the customer upon completion of defined milestones. As these payments are received, they are offset against accumulated project costs and recorded as either contract assets or contract liabilities. Upon completion of the performance obligations and collectability is determined, revenue is recorded. For any contract that is expected to incur costs in excess of the contract price, the Company accrues the estimated loss in full in the period such determination is made.

Contract Acquisition Costs and Practical Expedients

For contracts that have a duration of less than one year, the Company follows ASC 606, Narrow Scope Improvements and Practical Expedients, and expenses those costs when incurred. For contracts with a life exceeding one year, the Company records those costs when performance obligations related to the contract are completed. The Company generally expenses sales commissions when incurred. The Company amortizes those costs within general and administrative expenses over the life of the contract.

6

Table of Contents

Product Warranties

The Company warrants all installed products against defects in materials and workmanship for a period specified in each contract by replacing failed parts. Accruals for product warranties are based on historical or expected warranty experience and current product performance trends and are recorded as a component of cost of sales at the time revenue is recognized. The warranty liabilities are reduced by material and labor costs used to replace parts over the warranty period in the periods in which the costs are incurred. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary, and such adjustments could be material in the future if estimates differ significantly from actual warranty expense. Product warranties are included in accrued liabilities in the balance sheets.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash on deposit in a checking and savings account.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivables are recorded at the contractual invoiced amount. An allowance for doubtful accounts is established, as necessary, based on past experience and management’s judgment. The determination of the collectability of amounts due from customers require the Company to make judgments regarding future events and trends. Allowances for doubtful accounts are determined based on assessing the Company’s portfolio on an individual customer and on an overall basis. This process consists of a review of historical collection experience, current aging status of the customer accounts, and the financial condition of the Company’s customers. Based on a review of these factors, the Company may establish or adjust the allowance for specific customers and the accounts receivable portfolio as a whole.

Fixed Assets and Leases

Fixed assets are recorded at cost. Leases are recorded in accordance with FASB ASC 842, Leases. For those leases with a term greater than one year, the Company recognizes a right-of-use asset and a lease liability measured at the present value of the lease payments at the time of the lease inception or modification. Lease costs are recognized in the income statement over the lease term on a straight-line basis. Leases with a term of 1 year or less are considered short term leases with rent expense recognized over the lease term. Depreciation is computed using the straight-line method over the estimated useful lives of the respective lease assets. Leasehold improvements are depreciated over the life of the lease or their useful life, whichever is shorter. All other fixed assets are depreciated over three to four years. Maintenance and repairs are expensed as incurred.

7

Table of Contents

Patents and Trademarks

Third-party expenses related to patents and trademarks are recorded at cost, less accumulated amortization. Amortization is computed using the straight-line method over the estimated useful lives of the assets once they are awarded. Patent application costs are deferred pending the outcome of patent and trademark applications. Costs associated with unsuccessful patent applications and abandoned intellectual property are expensed when determined to have no continuing value in current business activity. We evaluate the recoverability of the carrying values of intangible assets each reporting period.

Impairment of Long-Lived Assets

The Company tests long-lived assets, consisting of fixed assets, patents, trademarks, and other intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable through the estimated undiscounted cash flows expected from the use and eventual disposition of the assets. In the event an asset is not fully recoverable a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Fair value is determined based on the present value of estimated expected cash flows using a discount rate commensurate with the risks involved, quoted market prices, or appraised values depending upon the nature of the assets. Losses on long-lived assets to be disposed of is determined in a similar manner, except those fair values are reduced for the cost of disposal.

Fair Value of Financial Instruments

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities measured at fair value are categorized based on whether or not the inputs are observable in the market and the degree that the inputs are observable. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The three levels of inputs used to establish fair value are the following:

| ● | Level 1 – Quoted prices in active markets for identical assets or liabilities.

| ● | Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

| ● | Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company’s financial instruments primarily consist of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses. As of the balance sheet dates, the estimated fair values of the financial instruments were not materially different from their carrying values as presented on the balance sheets. This is primarily attributable to the short-term nature of these instruments.

The Company did not identify any other recurring or non-recurring assets and liabilities that are required to be presented in the balance sheets at fair value.

8

Table of Contents

Research and Development

The cost of research and development is expensed as incurred. Research and development costs consist of salaries, benefits, share based compensation, consumables, and consulting fees, including costs to develop and test prototype equipment and parts. Research and Development costs have been offset by funds received, if any, from strategic partners in cost sharing, collaborative projects. During the three months ended March 31, 2022 and March 31, 2021, the Company did not receive any funds from such arrangements to partially offset funding for research and development activities.

Income Taxes

The Company accounts for income taxes using an asset and liability approach which allows for the recognition and measurement of deferred tax assets based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not the Company would not be able to realize their benefits, or that future deductibility is uncertain. Tax benefits are recognized only if it is more likely than not that the tax benefits will be utilized in the foreseeable future.

Share-Based Compensation

The costs of all employee stock options, as well as other equity-based compensation arrangements, are reflected in the unaudited condensed consolidated financial statements based on the estimated fair value of the awards on the grant date. That cost is recognized over the period during which an employee is required to provide service in exchange for the award, or in the case of performance options, expense is recognized upon completion of a milestone as defined in the grant agreement. Share-based compensation for stock grants to non-employees is determined as the fair value of the consideration received or the fair value of equity instruments issued, whichever is more reliably measured.

Foreign Operations

The accompanying unaudited condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021 include assets amounting to approximately $227 thousand and $274 thousand, respectively, relating to operations of ClearSign Asia Limited. The Beijing registered capital requirement is $350 thousand, which is required to be paid by 2027, and of which none has been paid to date. It is always possible that unanticipated events in foreign countries could disrupt the Company’s operations, and since the first quarter of 2020 this has been and currently continues to be the case with the effects of the recent COVID-19 pandemic.

Foreign Currency

Assets and liabilities of ClearSign Asia Limited with non-U.S. Dollar functional currency are translated to U.S. Dollars using exchange rates in effect at the end of the period. Revenue and expenses are translated to U.S. Dollars using rates that approximate those in effect during the period. The resulting translation adjustments are included in the Company’s condensed consolidated balance sheets in the stockholders’ equity section as a component of accumulated other comprehensive gain (loss).

​

Noncontrolling Interest

The subsidiary of the Company has a minority shareholder agreement representing an ownership interest of 1.00% of ClearSign Asia Limited. The Company accounts for this noncontrolling interest pursuant to FASB ASC 810 whereby gains and losses in a subsidiary with a noncontrolling interest are allocated to the noncontrolling interest based on the ownership percentage of the noncontrolling interest, even if that allocation results in a deficit noncontrolling interest balance.

9

Table of Contents

Net Loss per Common Share

Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include additional common shares available upon exercise of stock options and warrants using the treasury stock method, except for periods for which no common share equivalents are included because their effect would be anti-dilutive. At March 31, 2022 and December 31, 2021, potentially dilutive shares outstanding amounted to 3.3 million and 3.1 million, respectively.

Recently Issued Accounting Pronouncements

In June 2017, the FASB issued an Accounting Standards Update (ASU) 2016-13, Financial Instruments (Topic 326) Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. The standard replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. ASU 2016-13, and related amendments, are effective for fiscal years beginning after December 15, 2022. The Company has not completed its assessment of the standard but does not expect the adoption to have a material impact on its financial statements.

​

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which outlines disclosure requirements for entities that receive assistance from a government body. ASU 2021-10, and related amendments, are affective for annual reports beginning after December 15, 2021. The Company does not expect the adoption to have a material impact on its financial statements.

​

Note 3 Fixed Assets

Fixed Assets

Fixed assets are summarized as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | December 31, | ​
(in thousands) |  | 2022 |  | 2021 |
Machinery and equipment | ​ | $ | 666 | ​ | $ | 722 | ​
Office furniture and equipment | ​ |  | 224 | ​ |  | 218 | ​
Leasehold improvements | ​ |  | 192 | ​ |  | 192 | ​
​ | ​ | ​ | 1,082 | ​ | ​ | 1,132 | ​
Accumulated depreciation and amortization | ​ |  | (1,006) | ​ |  | (1,055) | ​
​ | ​ | ​ | 76 | ​ | ​ | 77 | ​
Operating lease ROU assets, net | ​ | ​ | 417 | ​ | ​ | 453 | ​
Total | ​ | $ | 493 | ​ | $ | 530 | ​

​

Depreciation expense for the three months ended March 31, 2022 and 2021 totaled $7 thousand and $8 thousand, respectively.

Leases

The Company leases office space in Seattle, Washington, Tulsa, Oklahoma and Beijing, China. The Beijing lease is treated as a short-term lease. The monthly rent for the Beijing lease is approximately $5 thousand.

​

The Seattle and Tulsa leases are classified as operating leases, with remaining terms ranging from one to six years; contractual language requires renewal negotiations to occur at or near termination. These leases are normal and customary for office space, in that, contractual guarantees exist requiring the lessee to return the premises to its original functional state. In 2021, the Company accrued an estimated cost of $32 thousand to prepare for the restoration of the Seattle office. The Company plans to exit the Seattle lease on or before contract termination as part of our headquarters

10

Table of Contents

move from Seattle to Tulsa. In preparation for this move, the Company entered into the Tulsa operating lease agreement in April 2021.

​

The Seattle and Tulsa leases contain fixed annual lease payments that increase annually by factors that range between 2% to 3%. Total monthly minimum rent is approximately $24 thousand. Contractual agreements contain expiration dates ranging from less than twelve months to less than six years.

Supplemental balance sheet information related to operating leases is as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | March 31, | ​ | ​ | December 31, | ​
(in thousands) | ​ | ​ | 2022 | ​ | ​ | 2021 | ​
Operating lease ROU assets, net | ​ | $ | 417 | ​ | $ | 453 | ​
Lease Liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Current lease liabilities | ​ | $ | 212 | ​ | $ | 205 | ​
Long term lease liabilities | ​ | ​ | 294 | ​ | ​ | 350 | ​
Total lease liabilities | ​ | $ | 506 | ​ | $ | 555 | ​

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | For the Three Months Ended | ​
​ | ​ | ​ | March 31, | ​
​ | ​ |  | 2022 | ​ | ​ | 2021 | ​
Operating lease costs | ​ | $ | 57 | ​ | $ | 51 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Supplemental cash flow information related to leases is as follows: | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash paid for amounts included in the measurement of lease liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating cash flows from operating leases | ​ | $ | 57 | ​ | $ | 53 | ​
Non-cash impact of new leases and lease modifications | ​ | ​ | ​ | ​ | ​ | ​ | ​
New operating lease liabilities | ​ | $ | — | ​ | $ | 320 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted average remaining lease term (in years): | ​ |  | 2.6 | ​ | ​ | ​ | ​
Weighted average discount rate: | ​ |  | 5.8 | % | ​ | ​ | ​

​

​

Minimum future payments under the Company’s lease liabilities at March 31, 2022 are as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Discounted |  | Payments
​ | ​ | lease | ​ | due under
(in thousands) | ​ | liability | ​ | lease
​ | ​ | payments | ​ | agreements
2022 (remaining 9 months) |  | $ | 158 |  | $ | 176
2023 |  | ​ | 122 |  | ​ | 136
2024 | ​ | ​ | 54 | ​ | ​ | 64
2025 | ​ | ​ | 59 | ​ | ​ | 66
2026 | ​ | ​ | 63 | ​ | ​ | 67
Thereafter | ​ | ​ | 50 | ​ | ​ | 51
Total | ​ | $ | 506 | ​ | $ | 560

​

At March 31, 2022, $56 thousand of our future minimum lease payments represented interest.

​

​

​

​

11

Table of Contents

Note 4 – Patents and Other Intangible Assets

Patents and other intangible assets are summarized as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | December 31, | ​
(in thousands) |  | 2022 |  | 2021 |
Patents | ​ | ​ | ​ | ​ | ​ | ​ | ​
Patents pending | ​ | $ | 473 | ​ | $ | 439 | ​
Issued patents | ​ |  | 577 | ​ |  | 577 | ​
​ | ​ |  | 1,050 | ​ |  | 1,016 | ​
Trademarks | ​ |  | ​ | ​ |  | ​ | ​
Trademarks pending | ​ |  | 1 | ​ |  | 3 | ​
Registered trademarks | ​ |  | 95 | ​ |  | 94 | ​
​ | ​ |  | 96 | ​ |  | 97 | ​
Other | ​ |  | 8 | ​ |  | 8 | ​
​ | ​ |  | 1,154 | ​ |  | 1,121 | ​
Accumulated amortization | ​ |  | (352) | ​ |  | (322) | ​
​ | ​ | $ | 802 | ​ | $ | 799 | ​

​

Future amortization expense associated with issued patents and registered trademarks as of March 31, 2022 is as follows:

​

​ | ​ | ​ | ​
(in thousands) | ​ | ​ | ​
2022 (remaining 9 months) |  | $ | 88
2023 | ​ |  | 96
2024 | ​ |  | 74
2025 | ​ |  | 42
2026 | ​ |  | 9
Thereafter | ​ |  | 11
​ | ​ | $ | 320

​

The amortization life for patents ranges between three to five years, with trademark lives set at ten years. The Company does not amortize patents or trademarks classified as pending.

​

During the three months ended March 31, 2022 and 2021, the Company assessed its patent and trademark assets. The Company also evaluated its strategic approach to the pursuit and protection of its intellectual property. It is the intent of the Company to continue to pursue intellectual property protection.

​

If the Company identifies certain assets where the intellectual property does not directly align with our core technology, we will impair the intangible asset and write-off any monies to research and development expense.

​

​

Note 5 – Revenue, Contract Assets and Contract Liabilities

The Company recognized no revenues during the three months ended March 31, 2022 and $363 thousand of revenue during the three months ended March 31, 2021 from the completion and delivery of a burner under a product contract with an infrastructure company.

​

The Company did no t record any cost of goods sold for the three months ended March 31, 2022. During the three months ended March 31, 2021, the Company recognized cost of goods sold of $250 thousand from the burner contract. Additionally, the Company recognized $18 thousand in cost of goods sold on a contract that the Company estimated would show a loss upon completion, and $8 thousand in residual costs associated with a contract that was completed during 2020. The recognized cost of goods sold was offset by adjustments totaling $51 thousand related to the reversal of accrual for product warranties that expired on three completed projects from the year 2018.

​

12

Table of Contents

The Company had contract assets of $244 thousand and $39 thousand at March 31, 2022 and December 31, 2021, respectively. The Company had contract liabilities of $84 thousand at March 31, 2022 and December 31, 2021.

​

Note 6 – Equity

Common Stock and Preferred Stock

The Company is authorized to issue 62.5 million shares of common stock and 2.0 million shares of preferred stock. Preferences, limitations, voting powers and relative rights of any preferred stock to be issued may be determined by the Company’s Board of Directors. The Company has not issued any shares of preferred stock.

In July 2018, the Company completed a private equity offering and executed a Stock Purchase Agreement with clirSPV, LLC which permits participation in future capital raising transactions (Participation Right) on the same terms as other investors participating in such transactions. The Participation Right will expire on December 31, 2023. In no event may the Participation Right be exercised to the extent it would cause clirSPV, LLC or any of its affiliates to beneficially own 20% or more of the Company’s then outstanding common stock or hold shares with 20% or more of the voting power.

​

During the three months ended March 31, 2022, the Company issued approximately 496 thousand shares of its common stock at an average price of $1.24 per share for gross proceeds of approximately $614 thousand pursuant to an At-The-Market (ATM) Offering Sales Agreement with Virtu Americas LLC, as sales agent pursuant to which it may sell shares of common stock with an aggregate offering price of up to $15.0 million. As of March 31, 2022, the Company has issued approximately 1.6 million shares of common stock under the ATM program, at an average price of $3.85 per share. Gross proceeds totaled approximately $6.1 million and net cash proceeds was approximately $5.9 million.

​

Equity Incentive Plan

On June 17, 2021, the Company's shareholders approved and the Company adopted the ClearSign Technologies Corporation 2021 Equity Incentive Plan (2021 Plan) which permits the Company to grant Incentive Stock Options, Non-statutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units, and Performance Shares, to eligible participants, which includes employees, directors and consultants. The Compensation Committee of the Board of Directors is authorized to administer the 2021 Plan.

​

The 2021 Plan provides for an annual increase in available shares equal to the lessor of (i) 10% of the aggregate number of shares of Common Stock issued by the Company in the prior fiscal year; or (ii) such number provided by the Compensation Committee; provided, however, that the total cumulative increase in the number of shares available for issuance pursuant to this automatic share increase shall not exceed 400 thousand shares of common stock. In 2022, the board of directors approved an increase of 150,423 shares.

Ending balances of the Plans are as follows:

​

​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | December 31,
(in thousands) |  | 2022 |  | 2021
Outstanding options and restricted stock units |  | 3,307 |  | 3,076
Reserved but unissued shares under the Plans | ​ | 2,758 | ​ | 2,901
Total authorized shares under the Plans |  | 6,065 |  | 5,977

​

Stock Options

​

Under the terms of the 2021 Plan, incentive stock options and nonstatutory stock options must have an exercise price at or above the fair market value on the date of the grant. At the time of grant, the Company will determine the period within which the option may be exercised and will specify any conditions that must be satisfied before the option vests and may be exercised. The Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model.

​

13

Table of Contents

As permitted by SEC Staff Accounting Bulletin (SAB) 107, management utilized the simplified approach to estimate the expected term of the options, which represents the period of time that options granted are expected to be outstanding. Expected volatility has been determined through the Company’s historical stock price volatility. The Company has not made an estimate of forfeitures at the time of the grant, but rather accounts for forfeitures at the time they occur. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield in effect at the time of grant. The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.

​

The following weighted-average assumptions were utilized in the calculation of the fair value of stock options:

​

​ | ​ | ​ | ​
​ | ​ | March 31, | ​
​ | ​ | 2022 | ​
Expected life |  | 5.71 years |
Weighted average volatility | ​ | 77.64 | %
Weighted average risk-free interest rate | ​ | 1.39 | %
Expected dividend rate | ​ | 0 | %

​

Compensation expense for stock option awards was $42 thousand and $410 thousand for the three months ended March 31, 2022 and 2021, respectively.

​

A summary of the Company’s stock option activity and changes is as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31,
​ | ​ | 2022
​ | ​ | ​ | ​ | ​ | ​ | ​ | Weighted
​ | ​ | ​ | ​ | ​ | ​ | ​ | Average
​ | ​ | Options to | ​ | Weighted | ​ | Remaining
​ | ​ | Purchase | ​ | Average | ​ | Contractual
​ | ​ | Common | ​ | Exercise | ​ | Life (in
(in thousands) |  | Stock |  | Price |  | years)
Outstanding at January 1 |  | 2,964 | ​ | $ | 2.06 |  | 6.89
Granted |  | 88 | ​ | $ | 1.26 |  | 9.76
Exercised |  | (3) | ​ | $ | 0.89 |  | —
Forfeited/Expired |  | (10) | ​ | $ | 2.93 |  | —
Outstanding at March 31 |  | 3,039 | ​ | $ | 2.03 |  | 6.76
Exercisable at March 31 |  | 2,202 | ​ | $ | 1.71 |  | 6.05

​

The estimated aggregate pretax intrinsic value of the Company’s outstanding vested stock options at March 31, 2022 is $848 thousand. The intrinsic value is the difference between the Company’s common stock price and the option exercise prices multiplied by the number of in-the-money options. This amount changes based on the fair value of the Company’s common stock.

​

At March 31, 2022, there was $1.8 million of total unrecognized compensation cost related to non-vested stock option-based compensation arrangements. Vesting criteria ranges from time-based to performance-based. The Company records costs for time-based arrangements ratably across the timeframe, whereas performance-based arrangements require management to continually evaluate predetermined goals against actual circumstances.

​

Restricted Stock Units

The Company approved compensation for board service to be paid to its independent directors in restricted stock units (“RSUs”) under the 2021 Plan. Compensation is earned on a quarterly basis with the target value of compensation set at $85 thousand per quarter. A RSU grant is to be awarded to each independent director in the beginning of the quarter in which services will be rendered, and the number of RSUs granted is to be based on the trading value of the Company’s stock on the date of the award.

14

Table of Contents

The vesting of the RSU grants is contingent upon the occurrence of one of four future events which the Company cannot predict or control. Accordingly, stock based compensation has not been recognized for services performed during each of the three months ended March 31, 2022 or 2021 in accordance with FASB Accounting Standards Codification, Topic 718, Compensation-Stock Compensation, (ASC 718). During the three months ended March 31, 2022, the Company issued 59 thousand RSUs for board services amounting to $85 thousand of unrecognized compensation.

During January 2022, the Company issued retention bonuses for employees in the form of RSUs. These awards vest 12 months from the date of award for services rendered in 2022. During the three months ended March 31, 2022, the Company issued 97 thousand RSUs to employees amounting to $35 thousand of recognized compensation and $105 thousand for unrecognized compensation.

Stock Grants

During the three months ended March 31, 2022, the Company issued 66 thousand shares of common stock with a fair value of $1.44 per share to its employees. These shares were issued in lieu of cash for payment of 2021 accrued bonuses totaling $125 thousand that were recorded during the year ended December 31, 2021. In addition, the Company issued 3 thousand shares for a one-time $3 thousand bonus to one employee in recognition of their performance.

Consultant Stock Plan

The 2013 Consultant Stock Plan (the Consultant Plan) provides for the granting of shares of common stock to consultants who provide services related to capital raising, investor relations, and making a market in or promoting the Company’s securities. The Company’s officers, employees, and board members are not entitled to receive grants from the Consultant Plan. The Compensation Committee of the Board of Directors is authorized to administer the Consultant Plan and establish the grant terms. The Consultant Plan provides for quarterly increases in the available number of authorized shares equal to the lesser of 1% of any new shares issued by the Company during the quarter immediately prior to the adjustment date or such lesser amount as the Board of Directors shall determine.

​

The Consultant Plan activity and change is as follows:

​

​ | ​ | ​ | ​
​ | ​ | March 31,
(in thousands) |  | 2022
Reserved but unissued shares January 1 | ​ | ​ | 211
Grants | ​ | ​ | (4)
Reserved but unissued shares | ​ |  | 207

​

The Consultant Plan compensation expense is summarized as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the Three Months Ended
​ | ​ | March 31,
​ |  | 2022 |  | 2021
Compensation Expense | ​ | $ | 7 | ​ | $ | 9
Weighted Average Value Per Share | ​ | $ | 1.93 | ​ | $ | 2.33

​

15

Table of Contents

Inducement Stock Options

Pursuant to the rules of The Nasdaq Stock Market, and in compliance with those rules, the Company may issue equity awards, including stock options, as an inducement to an individual to accept employment with the Company. Inducement awards need not be approved by the Company's shareholders. During the year ended December 31, 2019, the Company granted 341 thousand non-qualified stock options to its Chief Executive Officer. The fair value of the non-qualified stock options estimated on the date of grant using the Black-Scholes valuation model was $176 thousand. The compensation expense recognized for these awards for the three months ended March 31, 2022 and 2021 was zero and $13 thousand, respectively.

Note 7 – Commitments and Contingencies

Litigation

From time to time the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties and an adverse result in any such matter may harm the Company’s business. As of the date of this report, the Company is not a party to any material pending legal proceedings or claims that the Company believes will have a material adverse effect on the business, financial condition or operating results.

Indemnification Agreements

The Company maintains indemnification agreements with our directors and officers that may require the Company to indemnify these individuals against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by law.

​

Note 8 – The Paycheck Protection Program (PPP) Loan

​

On May 8, 2020, the Company obtained a loan in the amount of $251 thousand (the “PPP loan”) from Bank of America (the “Lender”), pursuant to the Paycheck Protection Program (the “PPP”) under the Coronavirus Aid, Relief, and Economics Security Act (the “CARES Act”) that was signed into law in March 2020. In accordance with the PPP, the Company was permitted to use the PPP loan proceeds to fund designated expenses, including certain payroll costs, rent, utilities, and other permitted expenses. The PPP loan was evidenced by a promissory note, dated effective May 1, 2020, issued by the Company to the Lender. The PPP loan was unsecured with a 2-year term and bore interest at a rate of 1.00% per annum. The Company applied with the Small Business Administration, ("SBA") for loan forgiveness in January 2021. Payments on this note were deferred by the Lender until the forgiveness status of the loan was ascertained. In the second quarter of 2021, the Company received documentation from the SBA stating that this loan was forgiven in full. As a result, the Company recorded a $251 thousand gain on forgiveness of debt and accrued interest during the three months ended June 30, 2021.

​

​

16

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION CONTAINED IN THIS REPORT

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. You can find many (but not all) of these statements by looking for words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “would,” “should,” “could,” “may,” “will” or other similar expressions in this report. In particular, these include statements relating to future actions; prospective products, applications, customers, and technologies; future performance or results of any products; anticipated expenses; and future financial results. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations or projections. Factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to:

| ● | our limited cash, history of losses, and our expectation that we will continue to experience operating losses and negative cash flows in the near future;

| ● | our limited operating history;

| ● | emerging competition and advancing technology in our industry that may outpace our technology;

| ● | changes in government regulations that could substantially reduce, or even eliminate, the need for our technology;

| ● | customer demand for the products and services we develop;

| ● | the impact of competitive or alternative products, technologies, and pricing;

| ● | our ability to manufacture any products we design;

| ● | our doing business in China and related risks with respect to intellectual property protection, currency exchange, contract enforcement and rules on foreign investment;

| ● | the impact of a cybersecurity incident or other technology disruption;

| ● | our ability to protect our intellectual property;

| ● | our ability to obtain adequate financing in the future;

| ● | our ability to retain and hire personnel with the experience and talent to develop our products and business;

| ● | general economic conditions and events and the impact they may have on us and our potential customers;

| ● | our ability to obtain adequate financing in the future to support our operations;

| ● | lawsuits, investigations, and other claims by third parties or regulatory agencies, including but not limited to, the Securities and Exchange Commission, Internal Revenue Service, Financial Industry Regulatory Authority;

| ● | the financial and operational impacts of the coronavirus pandemic on our business and results of operations, including impacts on our day-to-day operations, collaborative arrangements, revenue and marketing efforts and suppliers;

17

Table of Contents

| ● | our success at managing the risks involved in the foregoing items; and

| ● | other factors discussed in this report and in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K.

Forward-looking statements may appear throughout this report, including, without limitation, Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” The forward-looking statements are based upon management’s beliefs and assumptions and are made as of the date of this report. We undertake no obligation to publicly update or revise any forward-looking statements included in this report. You should not place undue reliance on these forward-looking statements.

Unless otherwise stated or the context otherwise requires, the terms “ClearSign,” “we,” “us,” “our” and the “Company” refer to ClearSign Technologies Corporation and its subsidiary, ClearSign Asia Limited.

​

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited consolidated condensed financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q as well as our audited financial statements and related notes included in our most recent Annual Report on Form 10-K. In addition to historical information, this discussion and analysis here and throughout this Form 10-Q contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements due to a number of factors, including but not limited to, the risks described in the section titled “Risk Factors” in our Annual Report on Form 10-K.

​

OVERVIEW

​

We design and develop technologies for the purpose of improving key performance characteristics of combustion systems, including emission and operational performance, energy efficiency and overall cost-effectiveness. Our ClearSign Core™ technology has been proven in full scale industrial test furnaces and boilers and first customer installations are currently operating in normal commercial use. We have generated nominal revenues from operations to date to meet operating expenses.

​

We have incurred losses since inception totaling $84.3 million and we expect to experience operating losses and negative cash flow for the foreseeable future. We have historically financed our operations primarily through issuances of equity securities. Since inception, we have raised approximately $84.6 million in gross proceeds through the sale of our equity securities. We may need to raise additional capital in the future, however, the significant volatility in the capital markets may negatively affect our ability to raise this additional capital.

​

It is not possible at this time to estimate the full impact that the coronavirus pandemic will have on our business or on our potential customers, suppliers, or other business partners. However, the continued spread of the coronavirus, the measures taken by the governments of affected countries, actions taken to protect employees, the limitations placed on travel and border crossings, and the impact of the pandemic on various business activities in affected countries could adversely impact our operational results and financial condition.

​

In order to generate meaningful revenues, our technologies must gain market recognition and acceptance to develop sufficient recurring sales. In addition, management believes that the successful growth and operation of our business is dependent upon our ability to obtain adequate sources of funding through co-development agreements, strategic partnering agreements, or equity or debt financing to adequately support commercialization of our research and development efforts, protect intellectual property, form relationships with strategic partners and provide for working capital and general corporate purposes. There can be no assurance that we will be successful in achieving our long-term plans, or that such plans, if consummated, will result in profitable operations or enable us to continue in the long-term as a going concern.

18

Table of Contents

​

Our costs include employee salaries and benefits, compensation paid to consultants, materials and supplies for prototype development and manufacture, costs associated with development activities including materials, sub-contractors, travel and administration, legal and accounting expenses, sales and marketing costs, general and administrative expenses, and other costs associated with an early stage, publicly traded technology company. We currently have 14 full-time employees. Because using third party expertise and resources is more efficient than maintaining full time resources, we also expect to incur ongoing consulting expenses related to technology development and some administrative, sales and legal functions commensurate with our current level of activities.

​

The amount that we spend for any specific purpose may vary significantly, and could depend on a number of factors including, but not limited to, the pace of progress of our commercialization and development efforts, actual needs with respect to product testing, development and research, market conditions, and changes in or revisions to our sales and marketing strategies.

​

Research, development, and commercial acceptance of new technologies are, by their nature, unpredictable. Although we undertake development and commercialization efforts with reasonable diligence, there can be no assurance that the net proceeds from our securities offerings will be sufficient to enable us to develop our technology to the extent needed to create sufficient future sales to sustain operations. If the net proceeds from these offerings are insufficient for this purpose, we will consider other options to continue our path to commercialization, including, but not limited to, additional financing through follow-on equity offerings, debt financing, co-development agreements, sale or licensing of developed intellectual or other property, or other alternatives.

​

We cannot assure that our technologies will be accepted, that we will ever earn revenues sufficient to support our operations, or that we will ever be profitable. Furthermore, we have no committed source of financing, and we cannot assure that we will be able to raise money as and when we need it to continue our operations. If we cannot raise funds as and when we need them, we may be required to scale back our development plans by reducing expenditures for employees, consultants, business development and marketing efforts or to otherwise severely curtail, or even to cease, our operations.

​

CRITICAL ACCOUNTING POLICIES

​

The following discussion and analysis of financial condition and results of operations is based upon our financial statements, which have been prepared in conformity with accounting principles generally accepted in the United States of America. Certain accounting policies and estimates are particularly important to the understanding of our financial position and results of operations. These policies and estimates require the application of significant judgment by management. These estimates can be materially affected by changes from period to period as economic factors and conditions outside of our control change. As a result, they are subject to an inherent degree of uncertainty. In applying these policies, our management uses their judgment to determine the appropriate assumptions to be used in the determination of certain estimates. Those estimates are based on our historical operations, our future business plans and projected financial results, the terms of existing contracts, our observance of trends in the industry, information provided by our customers and information available from other outside sources, as appropriate. See Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this report for a more complete description of our significant accounting policies.

​

Revenue Recognition and Cost of Goods Sold. The Company recognizes revenue and related cost of goods sold in accordance with FASB ASC 606 Revenue from Contracts with Customers (ASC 606). Revenues and cost of goods sold are recognized once the goods or services are delivered to the customer’s control or non-refundable performance obligations are satisfied. The Company’s contracts with customers generally have performance obligations and a schedule of non-refundable cancellation obligations. The contracts generally will be fully performed upon delivery of certain documents or equipment. Revenue related to the contracts is recognized following the completion of non-refundable performance obligations as defined in the contract.

​

19

Table of Contents

The Company’s contracts generally include progress payments from customers upon completion of defined milestones. As these payments are received, they are offset against accumulated project costs and recorded as either contract assets or contract liabilities. Upon completion of the performance obligations and collectability is determined, revenue can be recorded. For any contract in connection with which the Company is expected to incur costs in excess of the contact price, the Company accrues the estimated loss in full in the period such determination is made.

​

Impairment of Long-Lived Assets

​

The Company tests long-lived assets, consisting of fixed assets, patents, and other intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable through the estimated undiscounted cash flows expected from the use and eventual disposition of the assets. In the event an asset in not fully recoverable a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Fair value is determined based on the present value of estimated expected cash flows using a discount rate commensurate with the risks involved, quoted market prices, or appraised values depending upon the nature of the assets. Losses on long-lived assets to be disposed of is determined in a similar manner, except those fair values are reduced for the cost of disposal.

​

Product Warranties

​

The Company warrants all installed products against defects in materials and workmanship, and shortcomings in performance compared to contractual guarantees for a period specified in each contract. Accruals for product warranties are based on expected warranty experience and current product performance trends which are recorded as a component of cost of sales at the time revenue is recognized. The warranty liabilities are reduced by material and labor costs during the warranty period in the periods in which the costs are incurred. The Company periodically assesses the adequacy of our recorded warranty liabilities and adjusts the amounts as necessary, and such adjustments could be material if estimates differ significantly from actual warranty expense. The warranty liabilities are included in accounts payable and accrued liabilities in the unaudited condensed consolidated balance sheets.

​

Research and Development

​

The cost of research and development is expensed as incurred. Research and development costs consist of salaries, benefits, share based compensation, consumables, and consulting fees, including costs to develop and test prototype equipment and parts. Research and development costs are offset by any funds received from strategic partners in cost sharing, collaborative projects.

​

Stock-Based Compensation

​

The costs of all employee stock options, as well as other equity-based compensation arrangements, are reflected in the unaudited, condensed consolidated financial statements based on the estimated fair value of the awards on the grant date. That cost is recognized over the period during which an employee is required to provide service in exchange for the award, or in the case of performance options, expense is recognized upon completion of a milestone as defined in the grant agreement. Stock-based compensation for stock grants to non-employees is determined as the fair value of the consideration received or the fair value of equity instruments issued, whichever is more reliably measured.

​

Fair Value of Financial Instruments

​

The Company's financial instruments primarily consist of cash and cash equivalents, accounts payable, accrued expenses and short-term investments in government securities. As of the balance sheet date, the estimated fair values of the financial instruments were not materially different from their carrying values as presented on the balance sheets. This is primarily attributed to the short maturities of these instruments.

​

20

Table of Contents

RESULTS OF OPERATIONS

​

Comparison of the Three Months Ended March 31, 2022 and 2021

​

Highlights of our quarter financial performance are as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the Three Months Ended | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | ​ | ​ | ​ | ​ | ​
(in thousands, except per share data) | ​ | 2022 |  | 2021 | ​ | $ Change | ​ | % Change
Revenues | ​ | $ | — | ​ | $ | 363 | ​ | $ | (363) | ​ | 100.0 | %
Cost of goods sold | ​ | ​ | — | ​ | ​ | 225 | ​ | $ | (225) | ​ | 100.0 | %
Gross Profit | ​ | ​ | — | ​ | ​ | 138 | ​ | $ | (138) | ​ | 100.0 | %
Operating Expenses | ​ | ​ | 1,517 | ​ | ​ | 2,159 | ​ | $ | (642) | ​ | 29.7 | %
Gain from sale of assets | ​ | ​ | 23 | ​ | ​ | ​ | ​ | $ | 23 | ​ | NA | ​
Other income, net | ​ | ​ | 4 | ​ | ​ | - | ​ | $ | 4 | ​ | NA | ​
Net loss | ​ | $ | (1,490) | ​ | $ | (2,021) | ​ | $ | 531 | ​ | 26.3 | %
Basic and diluted net income per common share | ​ | $ | (0.05) | ​ | $ | (0.07) | ​ | $ | 0.02 | ​ | 28.6 | %

​

​

Sales and Gross Profit

​

Consolidated revenues for the March 31, 2022 were zero compared to revenues of $363 thousand for the three months ended March 31, 2021. During the three months ended March 31, 2021, consolidated revenues included revenues from our burner product line for a sale that occurred in the United States.

​

Gross profit decreased by $138 thousand, or 100.0% compared to 2021. During the three months ended March 31, 2021 gross profit was generated by our burner product line.

​

Operating Expenses

​

Operating expenses consist of research and development (R&D) and general and administrative (G&A) expenses. These are addressed separately below.

​

R&D expenses decreased by $718 thousand or approximately 86.9% to $108 thousand for the three months ended March 31, 2022, as compared to $826 thousand during the three months ended March 31, 2021. During the three months ended March 31, 2022, we restructured our organization such that three engineers previously performing R&D functions were reassigned to business development, which shifted salaries of approximately $107 thousand to G&A expense. During the three months ended March 31, 2022, human capital and related incentive costs were also favorably impacted for headcount decreases of $123 thousand and incentive reductions of $166 thousand when compared to the three months ended March 31, 2021. In addition, we incurred $181 thousand less of product development costs as compared to three months ended March 31, 2021.

G&A expenses increased by $76 thousand or approximately 5.7% to $1,409 thousand during the three months ended March 31, 2022, as compared to $1,333 thousand during the three months ended March 31, 2021. During the three months ended March 31, 2022, we restructured our organization as discussed in more detail in previous paragraph, which resulted in an unfavorable $107 thousand dollar increase in salaries. G&A expenses were further unfavorably impacted by $122 thousand dollars for increased accounting costs. These costs related to temporary professional staff to reinforce the finance and accounting function after the death of our CFO in July 2021. G&A expenses were favorably impacted during the three months ended March 31, 2022 as a result of a $210 thousand decrease in compensation for board of director service. The decrease was due to two key factors: (i) changing payment of director compensation from stock options to restricted stock units, and (ii) deferring compensation expense as required by accounting standard ASC 718 Stock Compensation, refer to Note 6 Equity, for further details.

​

21

Table of Contents

Other Income

​

Other income for the three months ended March 31, 2022, includes a $23 thousand dollar gain from the sale of fixed assets at our Seattle office location. In January 2022, the board of directors approved the relocation of our headquarters from Seattle, Washington to Tulsa, Oklahoma. After approval, we began soliciting bids for our used lab and office equipment.

​

Net Loss

​

Net loss for the three months ended March 31, 2022, was $1,490 thousand compared to $2,021 thousand for the three months ended March 31, 2021, or an approximate 26.3% decrease. The $531 thousand decrease in net loss during the three months ended March 31, 2022 is primarily attributable to decreased human capital costs, and changing our board of directors compensation plan. Refer to our operating expenses discussion above for further details.

​

Liquidity and Capital Resources

​

At March 31, 2022, our cash and cash equivalent balance totaled $6,667 thousand compared to $7,607 thousand at December 31, 2021, a decrease of $940 thousand.

At March 31, 2022, our current assets were in excess of current liabilities resulting in working capital of $6,553 thousand as compared to $7,293 thousand at December 31, 2021.

Based on our current plans, we have sufficient funds to continue operating our business at current levels for at least 12 months from the date of issuance of this report. In order to continue business operations beyond that point, we currently anticipate that we will need to raise additional capital. Our development and general administrative costs are ongoing, and we expect to require additional funding to meet these expenses. To that end, we may undertake offerings of our securities, debt financings, selling or licensing intellectual property, or other alternatives. We filed a Form S-3 shelf registration statement with the Securities and Exchange Commission on June 27, 2019 that was declared effective on July 12, 2019. The registration statement allows us to offer common stock, preferred stock, warrants, subscription rights, debt securities and units from time to time as market conditions permit to fund the ongoing operations of the Company. Until the growth of revenue increases to a level that covers operating expenses it is the Company’s plan to continue to fund operations in this manner, although, as noted above, the significant volatility in the capital markets may negatively affect our ability to do so.

During the three months ended March 31, 2022, working capital has been funded with approximately $578 thousand in net proceeds from the ATM offering of 496 thousand shares of our common stock, offset by operating expenses. Subsequent to the three months ended March 31, 2022, the Company raised an additional $9 thousand in net proceeds from the ATM by issuing 5 thousand shares.

Operating activities for the three months ended March 31, 2022, resulted in cash outflows of $1,503 thousand, primarily due to the loss for the period of $1,490 thousand, offset with non-cash expenses of $100 thousand.

Operating activities for the three months ended March 31, 2021, resulted in cash outflows of $1,513 thousand, primarily due to the loss for the period of $2,021 thousand, offset with non-cash expenses of $771 thousand.

​

Investing activities for the three months ended March 31, 2022, resulted in cash outflows of $38 thousand in disbursements for fixed and intangible assets, and cash inflows of $23 thousand in proceeds from fixed asset sales, compared to cash outflows of $88 thousand in disbursements for fixed and intangible assets for the three months ended March 31, 2021.

Financing activities for the three months ended March 31, 2022, included $578 thousand in net proceeds from the sale of 496 thousand shares of our common stock through our ATM program at an average price of $1.24 per share.

22

Table of Contents

Financing activities for the three months ended March 31, 2021, included $3,393 thousand in net proceeds from the sale of 941 thousand shares of our common stock at an average price of $4.84 per share through our ATM program. The net proceeds were exclusive of $1,076 thousand that was receivable and collected after March 31, 2021. Financing activities for the three months ended March 31, 2021, also included $109 thousand from the exercise of option awards and warrants.

​

Off-Balance Sheet Transactions

​

We do not have any off-balance sheet transactions.

​

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

​

As a smaller reporting company, we are not required to provide this information.

​

ITEM 4.CONTROLS AND PROCEDURES

​

Disclosure Controls and Procedures

​

We maintain disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, (the “Exchange Act”), that are designed to reasonably ensure that information required to be disclosed in our reports filed under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal accounting and financial officer, as appropriate, to allow timely decisions regarding required disclosure.

​

We carried out an evaluation under the supervision and with the participation of management, including our Chief Executive Officer (principal executive officer) and our Vice President and Controller (principal accounting and financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2022, the end of the period covered by this Quarterly Report on Form 10-Q. Based upon the evaluation of our disclosure controls and procedures as of March 31, 2022, our Chief Executive Officer (principal executive officer) and our Vice President and Controller (principal accounting and financial officer) concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

​

Changes in Internal Control over Financial Reporting

​

There have been no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

​

Limitations on Effectiveness of Controls and Procedures

​

Our management, including our Chief Executive Officer (principal executive officer) and our Vice President and Controller (principal accounting and financial officer), does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or

23

Table of Contents

procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

​

PART II-OTHER INFORMATION

​

ITEM 1.LEGAL PROCEEDINGS

​

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

​

ITEM 1A.RISK FACTORS

​

We incorporate herein by reference the risk factors included under “Part I - Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2021, which we filed with the Securities and Exchange Commission on March 31, 2022, and the risk factors included in the reports and other documents we filed with the Securities and Exchange Commission subsequent to that date.

​

ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

​

On March 31, 2022, we issued 3,750 shares of common stock at a price per share of $1.93, the closing price of our common stock on November 19, 2021, the date of grant, from our 2013 Consultant Stock Plan to our investor relations firm, Firm IR, for services provided during the three months ended March 31, 2022. These shares were issued in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, for a transaction by an issuer not involving a public offering.

​

ITEM 3.DEFAULTS UPON SENIOR SECURITIES

​

Not applicable.

​

ITEM 4.MINE SAFETY DISCLOSURES

​

Not applicable.

​

ITEM 5.OTHER INFORMATION

The information set forth below is included herein for the purpose of providing the disclosure required under “Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers” of Form 8-K.

On May 11, 2022, we entered into an amendment (the “Amendment”) to the employment agreement, dated January 28, 2019 (the “Employment Agreement”), with our Chief Executive Officer, Colin James Deller, which (i) expanded the types of consideration available to satisfy Mr. Deller’s bonus compensation, from only stock options to also include cash or common stock, restricted stock, restricted stock units, performance stock or performance stock units issuable in accordance with the terms and conditions of our 2021 Equity Incentive Plan, as determined by the Compensation Committee of our Board of Directors, and (ii) increased the cash severance payment in connection with a termination of Mr. Deller’s employment, either by us upon not less than 30 days written notice or due to a Change of Control (as such term is defined in the Employment Agreement), from six months to one year of his annual base salary. The other provisions of the Employment Agreement not affected by the Amendment remain unchanged.

​

24

Table of Contents

The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which will be filed as an exhibit to our Quarterly Report on Form 10-Q for the quarter ending June 30, 2022.

​

ITEM 6.EXHIBITS

​

Exhibit | ​ | ​
Number |  | Document
​ | ​ | ​
3.1 | ​ | Articles of Incorporation of ClearSign Technologies Corporation (1)
3.2 | ​ | Bylaws, as amended effective September 8, 2021 (2)
31.1* | ​ | Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer
31.2* | ​ | Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer
32.1+ | ​ | Section 1350 Certification of Principal Executive Officer and Principal Financial Officer
101.INS | ​ | Inline XBRL Instance Document*
101.SCH | ​ | Inline XBRL Taxonomy Extension Schema Document*
101.CAL | ​ | Inline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF | ​ | Inline XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB | ​ | Inline XBRL Taxonomy Extension Label Linkbase Document*
101.PRE | ​ | Inline XBRL Taxonomy Extension Presentation Linkbase Document*
104 | ​ | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

​

*Filed herewith

+Furnished herewith

​

(1) | Incorporated by reference from the registrant’s Form 10-Q for the quarter ended September 30, 2019 filed with the Securities and Exchange Commission on November 13, 2019.

(2) | Incorporated by reference from the registrant’s Form 8-K filed with the Securities and Exchange Commission on September 10, 2021.

​

​

25

Table of Contents

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​ | ​ | CLEARSIGN TECHNOLOGIES CORPORATION
​ | ​ | ​
​ | ​ | ​
Date: May 16, 2022 | By: | /s/ Colin James Deller
​ | ​ | Colin James Deller
​ | ​ | Chief Executive Officer
​ | ​ | (Principal Executive Officer)

​

​

​ | ​ | ​
​ | ​ | ​
​ | ​ | ​
​ | By: | /s/ Brent Hinds
​ | ​ | Brent Hinds
​ | ​ | Vice President and Controller (Principal Financial and Accounting Officer)

​

​

​

26